Back to discover
Drug

Polyethylene Glycols

In clinical development
Emerging researchLate-stage developmentRising momentum
Also known as Hypotears, Macrogol, PEG, PEG - Polyethylene glycol+5 more

Hypotears, Macrogol, PEG, PEG - Polyethylene glycol, POLYETHYLENE GLYCOL, UNSPECIFIED, POLYOXYETHYLENE, Polyethylene Oxide, POLYETHYLENE GLYCOL, polythylene glycol.

3
Research papers
5
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Sarcomas

Clinical trial2026-02-19Results expected Q4 2028 · ClinicalTrials.gov

A review of current advancements for wound healing: Biomaterial applications and medical devices.

Research2022-05-17Journal of biomedical materials research. Part B, Applied biomaterials

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Polyethylene Glycols
Aliases & brands
HypotearsMacrogolPEGPEG - Polyethylene glycolPOLYETHYLENE GLYCOL, UNSPECIFIEDPOLYOXYETHYLENEPolyethylene OxidePOLYETHYLENE GLYCOLpolythylene glycol
RxNorm CUI
8516
ChEMBL ID
CHEMBL1201478
ATC codes
A06AD15A06AD65
UNII
3WJQ0SDW1A

Clinical trials

82 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
82
registered trials across all phases
LATEST COMPLETION 2026
5
Active studies
5
Recruiting
69
Late-stage (III+)
53
Completed
24
Discontinued
PHASE DISTRIBUTIONn = 82
Early Phase 11Phase 12Phase 1 / 23Phase 27Phase 2 / 33Phase 313Phase 427Phase N / A26

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20222025
Major research themes8
Cerium1Chitosan1Fibroins1Hydrogels1Metal Nanoparticles1Nanoparticles1Nerve Growth Factor1Nerve Regeneration1
Journals, researchers & institutions
Top journals
  • Journal of biomedical materials research. Part B, Applied biomaterials1
  • Journal of nanobiotechnology1
  • Nature communications1
Leading researchers
  • Ali MA1
  • Arrizabalaga S1
  • Chen Z1
  • Curtis A1
  • Deng X1
  • Gautam M1
  • Gong Z1
  • Gould M1
Leading institutions
free-text, unnormalised
  • Artemisinin Research Center1
  • Casey Eye Institute1
  • Centre for Bioengineering & Nanomedicine (Dunedin)1
  • College of Pharmacy1
  • Huashan Hospital1
  • Oregon Health & Science University1

Related drugs

6 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across the same disease area as Polyethylene Glycols in the shared literature.

1 shared disease1 shared paper

Frequently co-studied with Polyethylene Glycols in the research literature.

1 shared paper

Frequently co-studied with Polyethylene Glycols in the research literature.

1 shared paper

Frequently co-studied with Polyethylene Glycols in the research literature.

1 shared paper

Frequently co-studied with Polyethylene Glycols in the research literature.

1 shared paper

Frequently co-studied with Polyethylene Glycols in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials